Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Jan 14, 2014Phase 2 randomized trial will study Yervoy® and Prophage combination for metastatic melanoma
Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced initiation of a randomized Phase 2...
-
Jan 13, 2014
Agenus Inc. (Nasdaq: AGEN) a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced the appointment of Robert B. Stein,...
-
Jan 13, 20144-Antibody has a powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets
Agenus Inc. (Nasdaq: AGEN) a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced that it has entered into a definitive...
-
Dec 16, 2013
Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study...
-
Nov 18, 2013Agenus to present at 2013 Therapeutic Area Partnerships Conference
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that its Prophage Series (HSPPC-96) vaccine program for the treatment of brain...
